C. Randal Mills
Known title: PRESIDENT AND CEOCIK: 0001370939
C. Randal Mills's purchase track record
How the stock did after each of C. Randal Mills's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 13, 2025
Stock higher 6 months later
100%
3 months: 100%
Median 6-month return
+90.0%
3 months: +86.7%
Beat the S&P 500
100%
median +77.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2025 | ELUT | $2K | +113.9% | +96.2% | +10.4% |
| 11/24/2025 | ELUT | $3K | +86.7% | +90.0% | +12.1% |
| 11/13/2025 | ELUT | $10K | +28.0% | +40.0% | +11.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 9/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,718 | $8K | 9/10/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 22,473 | — | 6/21/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 8,064 | $9K | 6/21/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 6/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,718 | $10K | 6/10/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,084 | — | 3/10/2026 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 11,100 | $12K | 3/10/2026 | View on chart |
| ELUT | ▲ Buy | Open Market | 3,000 | $2K | 12/17/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 12/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,664 | $7K | 12/10/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 5,000 | $3K | 11/24/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 5,000 | $4K | 11/13/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 5,000 | $4K | 11/13/2025 | View on chart |
| ELUT | ▲ Buy | Open Market | 3,500 | $3K | 11/13/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 9/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,664 | $13K | 9/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 22,473 | — | 6/21/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 8,019 | $15K | 6/21/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,664 | $19K | 6/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,084 | — | 6/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 3/10/2025 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 10,706 | $32K | 3/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,083 | — | 12/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 13,726 | $59K | 12/10/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 27,084 | — | 9/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 9,664 | $40K | 9/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 58,659 | $167K | 8/12/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 162,500 | — | 8/12/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 8,019 | $28K | 6/21/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 22,473 | — | 6/21/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 54,167 | — | 6/10/2024 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 19,327 | $67K | 6/10/2024 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 22,474 | — | 6/21/2023 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 7,772 | $19K | 6/21/2023 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 44,947 | $0 | 4/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.